Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- ICH Meeting in Brussels Reported by Korosho
March 18, 2002
- Eisai Aims at Sales of \550 Bil. in FY2006: President Naito
March 18, 2002
- Reform Must Be Carried Out at Any Cost: Health Minister
March 18, 2002
- Giving Employees the Dream of Creating Major Firm: Mr Mascarenhas of Eli Lilly Japan
March 18, 2002
- Healthcare Reform Bills Approved by Government
March 18, 2002
- WORLD NEWS IN BRIEF
March 18, 2002
- BUSINESS NEWS IN BRIEF
March 18, 2002
- MEDICAL DEVICE NEWS IN BRIEF
March 18, 2002
- DIAGNOSTIC NEWS IN BRIEF
March 18, 2002
- OTC NEWS IN BRIEF
March 18, 2002
- Pharmacies Concerned about Effects of Revision of Medical Fees: Survey
March 18, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
March 18, 2002
- Importance of Training Rheumatologists Stressed: RDIC Seminar
March 18, 2002
- Nippon Roche to Participate in Multinational Study on Herceptin: JSMO Meeting
March 18, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 18, 2002
- REGULATORY NEWS IN BRIEF
March 18, 2002
- Committee to Propose Intellectual Property Strategy by Summer
March 18, 2002
- DIAGNOSTIC NEWS IN BRIEF
March 11, 2002
- OTS NEWS IN BRIEF
March 11, 2002
- NHI Price Revision in April Will Hit Drug Companies Hard: Mr Fujiyama of FPMAJ
March 11, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…